脉冲电场导管消融技术开发商Field Medical完成超额认购的3500万美元B轮融资，以推进FieldForce™脉冲场消融平台的开发-动脉网

Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform

CISION 等信源发布 2025-07-01 22:47



可切换为仅中文







BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market

BioStar资本和Cue Growth共同主导融资，以加速关键试验的准备，并扩大室性心动过速（VT）治疗市场。

New board leadership reflects Field's momentum and readiness for pivotal execution

新董事会领导层反映了Field的发展势头及其对关键执行的准备就绪。

CARDIFF-BY-THE-SEA, Calif.

卡迪夫海滩，加利福尼亚州

，

July 1, 2025

2025年7月1日

/PRNewswire/ -- Field Medical, Inc., a clinical-stage company redefining cardiac ablation with next-generation pulsed field ablation (PFA) technology, today announced the close of a

/PRNewswire/ -- Field Medical, Inc.是一家临床阶段公司，通过下一代脉冲场消融（PFA）技术重新定义心脏消融，今天宣布了

$35 million

3500万美元

Series B financing round co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors.

B轮融资由BioStar Capital和Cue Growth共同领投，现有战略投资者参与。

继续阅读

The FieldForce™ Ablation System by Field Medical: This next-generation PFA system is designed for transmural lesion creation, offering a novel approach to VT ablation.

Field Medical的FieldForce™消融系统：这款下一代PFA系统旨在实现透壁性病变创建，为室速消融提供了一种新颖的方法。

The Series B financing will support the initiation of the company's pivotal VERITAS trial, advance the FieldForce Ablation System development, and further expand Field Medical's clinical and regulatory capabilities. The raise was catalyzed in part by strong pilot data presented at the 2025 Heart Rhythm Society meeting.

B轮融资将支持公司启动关键的VERITAS试验，推动FieldForce消融系统开发，并进一步扩展Field Medical的临床和监管能力。此次融资部分得益于在2025年心律协会会议上展示的强有力的初步数据。

With this round, Field Medical has raised .

通过这一轮，Field Medical已经筹集了。

$75 million

7500万美元

to date, further solidifying its leadership in PFA innovation for complex arrhythmias.

到目前为止，进一步巩固了其在复杂心律失常PFA创新方面的领导地位。

'Ventricular tachycardia is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need,' said

“室性心动过速是电生理学中渗透率最低的细分领域之一，但医生仍然缺乏所需的工具，”

Steven Mickelsen

史蒂文·米克尔森

, MD, founder and CEO of Field Medical. 'What is exciting is how VT is mirroring the early days of the AF market, strong clinical demand unmet by existing technology. We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.'.

医学博士，Field Medical的创始人兼首席执行官表示：“令人兴奋的是，VT市场正如AF市场的早期阶段，现有技术无法满足强烈的临床需求。我们准备通过下一代治疗方案解锁这一机遇，该方案以速度、精准和真正的临床进展为核心，朝着关键性准备阶段迈进，并重新定义高危患者VT护理的可能性。”

'Field Medical's transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency,' said

“Field Medical的变革性技术正在做少数公司敢于做的事情——以真正的创新和紧迫感应对心脏病学中最困难且未被充分解决的挑战之一，”

Louis Cannon

路易斯·坎农

, MD, founder and senior managing director of BioStar Capital. 'Their physician-led team brings the right insight, and their FieldForce platform brings the right tools. We're proud to support this next chapter as they move closer to transforming VT care.'

，医学博士，BioStar Capital的创始人兼高级常务董事。“他们的医生领导的团队带来了正确的洞察力，他们的FieldForce平台带来了合适的工具。我们很自豪能支持他们迈向更接近转变VT护理的下一阶段。”

'This round reflects the momentum building behind Field Medical, not only from our clinical results, but also from the strength of our business fundamentals,' said Oskar Dadason, CFO of Field Medical. 'Our strong showing at HRS attracted institutional investor interest and reinforced continued support from existing investors, speaking volumes about the confidence in our technology, strategy, and leadership.'.

“这一轮融资反映了Field Medical背后的动力不断增强，不仅来自我们的临床成果，也来自我们业务基础的实力，”Field Medical的首席财务官奥斯卡尔·达达松表示。“我们在HRS的出色表现吸引了机构投资者的兴趣，并加强了现有投资者的持续支持，充分说明了对我们技术、战略和领导力的信心。”

Board of Directors Update

董事会更新

In alignment with its accelerated growth trajectory, Field Medical announced updates to its Board of Directors:

为了与其加速增长的轨迹保持一致，Field Medical 宣布了对其董事会的更新：

Steven Mickelsen

史蒂文·米克尔森

, MD,

，医学博士，

Founder and CEO, Field Medical

菲尔德医疗创始人兼首席执行官

– Electrophysiologist, serial entrepreneur, and inventor of pulsed field ablation technologies including FARAPULSE™ and FieldForce™.

电生理学家、连续创业者、脉冲场消融技术的发明者，包括FARAPULSE™和FieldForce™。

Mark Wisniewski

马克·维希涅夫斯基

，

CFO of Enterra Medical

Enterra Medical的首席财务官

– Medtech operator with deep buy-side experience and M&A leadership, guiding Field through its next phase of value creation as chairperson of the Field Medical board.

– 拥有深厚买方经验和并购领导能力的医疗技术运营商，作为Field Medical董事会主席，引领Field进入价值创造的下一阶段。

Marlou Janssen

马洛·扬森

，

Board Member at Field Medical, Sonion, Acarix, EBAMed, and Inspiration Healthcare

Field Medical、Sonion、Acarix、EBAMed 和 Inspiration Healthcare 的董事会成员

– Experienced executive and board member, former President of Biotronik U.S. and VP/GM at EPD Solutions Philips, bringing decades of commercial, product and clinical strategy leadership in cardiology and emerging medtech.

– 资深高管及董事会成员，曾任百多力美国总裁和飞利浦EPD解决方案副总裁/总经理，拥有数十年心脏病学和新兴医疗技术领域的商业化、产品和临床战略领导经验。

Alexei Mlodinow

阿列克谢·姆洛迪诺夫

, MD, MBA

，医学博士，工商管理硕士

– Surgeon by training, serial entrepreneur, and investor with a track record in medtech innovation and multiple exits, including the

– 外科医生出身，连续创业者和投资人，在医疗技术革新领域有着多次成功退出的记录，包括

$140M

1.4亿美元

acquisition of Surgical Innovation Associates.

收购外科创新协会。

Ben Cannon

本·坎农

，

Founding Partner, Cue Growth

创始合伙人，Cue Growth

– Seasoned venture capital investor with deep experience scaling growth-stage companies, offering institutional governance expertise and a performance-driven lens to support Field as the company scales.

- 资深风险资本投资者，拥有扩展成长阶段公司的深厚经验，提供机构治理专业知识和以绩效为导向的视角，支持Field公司在扩展过程中。

About Field Medical

关于现场医疗

Inc.

公司

Founded in 2022, Field Medical is advancing pulsed field ablation (PFA) technologies for the treatment of complex cardiac arrhythmias. Led by PFA pioneer Dr.

成立于 2022 年的 Field Medical 正在推进用于治疗复杂心律失常的脉冲场消融 (PFA) 技术。该公司由 PFA 先驱 Dr. 领导。

Steven Mickelsen

史蒂文·米克尔森

, the company's FieldForce™ Ablation System combines breakthrough catheter design with proprietary FieldBending™ energy to enable rapid, targeted ablation. In 2024, the company received Breakthrough Device Designation and was selected for the FDA TAP Pilot Program for its VT indication. To learn more about the company's clinical focus and technology, watch the Heart Rhythm 2025 Satellite Symposium replay, .

公司的FieldForce™消融系统结合了突破性的导管设计和独有的FieldBending™能量，能够实现快速、精准的消融。2024年，公司因其室性心动过速（VT）适应症获得了突破性设备指定，并被选入FDA TAP试点计划。欲了解更多关于公司的临床重点和技术信息，请观看Heart Rhythm 2025卫星研讨会回放。

PFA in the Ventricle: The Future of Ablation

心室中的PFA：消融的未来

。

For more information, visit

欲了解更多信息，请访问

www.fieldmedicalinc.com

and follow us on

关注我们

领英

and X.

和 X。

The FieldForce™ Ablation System is an investigational device and is limited by federal (or